Physician profile
Stuart Akerman
NPI 1154652923
$133,666.91
in general payments reported to CMS, 2019-2025
38 companies · $28K in 2025
The $28K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,299 · 2020: $2,715 · 2021: $15K · 2022: $3,722 · 2023: $12K · 2024: $68K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $95K · Consulting Fee: $5,200 · Food and Beverage: $4,862 · Travel and Lodging: $2,958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $95,156.25 |
| Consulting Fee | $5,200.00 |
| Food and Beverage | $4,861.76 |
| Travel and Lodging | $2,958.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $94,286.53 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $28,002.59 | 2021-2023 | |
| Allergan, INC. | $5,496.77 | 2019-2020 | |
| Abbvie INC. | $1,991.70 | 2019-2025 | Skyrizi, Rinvoq, Viberzi |
| Boston Scientific Corporation | $1,038.51 | 2019 | |
| Celgene Corporation | $347.68 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $256.62 | 2021-2025 | Stelara, Simponi Aria, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $217.70 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $194.12 | 2020-2025 | Xifaxan |
| Anx Robotica Corp | $182.10 | 2024 | |
| Mauna Kea Technologies, INC. | $144.30 | 2021 | |
| Pfizer INC. | $143.32 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $133.97 | 2020-2025 | Rebyota, Clenpiq |
| Abbott Laboratories | $113.52 | 2019-2022 | |
| Lilly USA, LLC | $113.06 | 2024-2025 | Omvoh |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien Lp | $99.32 | 2019-2020 | |
| Madrigal Pharmaceuticals | $94.45 | 2025 | Rezdiffra |
| Ardelyx, INC. | $93.51 | 2024-2025 | Ibsrela |
| Vivus LLC | $64.60 | 2024 | Qsymia |
| Iterative Scopes, INC. | $60.52 | 2024 | Skout |
| Phathom Pharmaceuticals, INC. | $58.17 | 2024 | Voquezna |
| Shionogi INC | $56.52 | 2019 | |
| Amgen INC. | $48.86 | 2023-2025 | Amjevita, Avsola, Uplizna |
| Axonics, INC. | $48.69 | 2023 | Axonics |
| Genzyme Corporation | $43.46 | 2024-2025 | |
| Medtronic, INC. | $42.70 | 2022-2024 | Gi Genius |
| Celltrion USA INC. | $42.60 | 2024-2025 | Vegzelma, Zymfentra |
| Daiichi Sankyo INC. | $41.31 | 2019 | |
| Alfasigma USA, INC. | $31.94 | 2020 | |
| Qol Medical, LLC | $31.81 | 2019-2024 | Sucraid |
| Evoke Pharma, INC. | $31.54 | 2024-2025 | |
| Enterra Medical, INC. | $28.92 | 2024 | |
| Braintree Laboratories, INC. | $25.48 | 2021 | |
| Stryker Corporation | $23.02 | 2024 | Neptune, Pedi-Pom |
| Ipsen Biopharmaceuticals, INC | $21.99 | 2025 | Iqirvo |
| Micro-Tech Endoscopy USA, INC. | $7.91 | 2020 | |
| Apollo Endosurgery US INC | $7.10 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$25,404.79 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Akerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.